Prediction of 177Lu-PRRT Kidney Absorbed Doses from Pretherapy SSTR-PET: Findings from Multicenter Data

摘要: 241988Introduction: Somatostatin receptor (SSTR) PET imaging is the standard of care for evaluation of a patient’s eligibility for 177Lu peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs). Pre-treatment SSTR-PET not only serves to ensure sufficient tumor SSTR-expression, but also holds promise as an effective tool for personalized PRRT by prediction of absorbed doses to critical organs prior to the treatment. The objective of this study is to validate the predictive capability of SSTR-PET in anticipating renal absorbed dose in the first cycle of 177Lu-PRRT using a multicenter dataset to analyze and derive insights from a broader patient population.Methods: : Data from five centers are included in this study: Canada (n=26), USA1 (n=24), Norway (n=75), Sweden (n=18) and USA2 (n=12). We evaluated the accuracy of univariate models for prediction of cycle 1 absorbed dose to kidney from …